Medexus Pharmaceuticals Inc. (TSX:MDP)

Canada flag Canada · Delayed Price · Currency is CAD
2.920
+0.090 (3.18%)
May 9, 2025, 3:58 PM EDT
70.76%
Market Cap 91.29M
Revenue (ttm) 157.61M
Net Income (ttm) 5.13M
Shares Out 32.26M
EPS (ttm) 0.21
PE Ratio 13.66
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 44,511
Average Volume 44,280
Open 2.850
Previous Close 2.830
Day's Range 2.845 - 2.980
52-Week Range 1.500 - 5.560
Beta 2.05
RSI 62.55
Earnings Date Apr 11, 2025

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical ... [Read more]

Sector Healthcare
CEO Kenneth d'Entremont
Employees 82
Stock Exchange Toronto Stock Exchange
Ticker Symbol MDP
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.